AIM: To assess blood chitinase 3-like 1 (CHi3L1) levels for 2 mo after minimally invasive colorectal resection (MICR) for colorectal cancer (CRC). METHODS: CRC patients in an Institutional Review Board approved data/plasma bank who underwent elective MICR for whom preoperative (PreOp), early postoperative (PostOp), and 1 or more late PostOp samples [postoperative day (POD) 7-27] available were included. Plasma CHi3L1 levels (ng/mL) were determined in duplicate by enzyme linked immunosorbent assay. RESULTS: PreOp and PostOp plasma sample were available for 80 MICR cancer patients for the study. The median PreOp CHi3L1 level was 56.8 CI: 41.9-78.6 ng/mL (n = 80). Significantly elevated (P < 0.001) median plasma levels (ng/mL) over PreOp levels were detected on POD1 (667.7 CI: 495.7, 771.7; n = 79), POD 3 (132.6 CI: 95.5, 173.7; n = 76), POD7-13 (96.4 CI: 67.7, 136.9; n = 62), POD14-20 (101.4 CI: 80.7, 287.4; n = 22), and POD 21-27 (98.1 CI: 66.8, 137.4; n = 20, P = 0.001). No significant difference in plasma levels were noted on POD27-41. CONCLUSION: Plasma CHi3L1 levels were significantly elevated for one month after MICR. Persistently elevated plasma CHi3L1 may support the growth of residual tumor and metastasis.
AIM: To assess blood chitinase 3-like 1 (CHi3L1) levels for 2 mo after minimally invasive colorectal resection (MICR) for colorectal cancer (CRC). METHODS: CRC patients in an Institutional Review Board approved data/plasma bank who underwent elective MICR for whom preoperative (PreOp), early postoperative (PostOp), and 1 or more late PostOp samples [postoperative day (POD) 7-27] available were included. Plasma CHi3L1 levels (ng/mL) were determined in duplicate by enzyme linked immunosorbent assay. RESULTS: PreOp and PostOp plasma sample were available for 80 MICR cancerpatients for the study. The median PreOp CHi3L1 level was 56.8 CI: 41.9-78.6 ng/mL (n = 80). Significantly elevated (P < 0.001) median plasma levels (ng/mL) over PreOp levels were detected on POD1 (667.7 CI: 495.7, 771.7; n = 79), POD 3 (132.6 CI: 95.5, 173.7; n = 76), POD7-13 (96.4 CI: 67.7, 136.9; n = 62), POD14-20 (101.4 CI: 80.7, 287.4; n = 22), and POD 21-27 (98.1 CI: 66.8, 137.4; n = 20, P = 0.001). No significant difference in plasma levels were noted on POD27-41. CONCLUSION: Plasma CHi3L1 levels were significantly elevated for one month after MICR. Persistently elevated plasma CHi3L1 may support the growth of residual tumor and metastasis.
Authors: Y Huang; M Prasad; W J Lemon; H Hampel; F A Wright; K Kornacker; V LiVolsi; W Frankel; R T Kloos; C Eng; N S Pellegata; A de la Chapelle Journal: Proc Natl Acad Sci U S A Date: 2001-12-18 Impact factor: 11.205
Authors: Catherine S M Diefenbach; Zharna Shah; Alexia Iasonos; Richard R Barakat; Douglas A Levine; Carol Aghajanian; Paul Sabbatini; Martee L Hensley; Jason Konner; William Tew; David Spriggs; Martin Fleisher; Howard Thaler; Jakob Dupont Journal: Gynecol Oncol Date: 2006-10-04 Impact factor: 5.482
Authors: Charlotte F J M Peeters; Lioe-Fee de Geus; Johan R Westphal; Robert M W de Waal; Dirk J Ruiter; Theo Wobbes; Wim J G Oyen; Theo J Ruers Journal: Surgery Date: 2005-02 Impact factor: 3.982
Authors: Julia S Johansen; Ib J Christensen; Rikke Riisbro; Michael Greenall; Chen Han; Paul A Price; Kenneth Smith; Nils Brünner; Adrian L Harris Journal: Breast Cancer Res Treat Date: 2003-07 Impact factor: 4.872
Authors: A Mitsuhashi; H Matsui; H Usui; Y Nagai; S Tate; Y Unno; K Hirashiki; K Seki; M Shozu Journal: Ann Oncol Date: 2008-08-22 Impact factor: 32.976
Authors: Stephanie T Chang; Jacob M Zahn; Joe Horecka; Pamela L Kunz; James M Ford; George A Fisher; Quynh T Le; Daniel T Chang; Hanlee Ji; Albert C Koong Journal: J Transl Med Date: 2009-12-11 Impact factor: 5.531
Authors: Tamara G Fong; Noel Y Chan; Simon T Dillon; Wenxiao Zhou; Bridget Tripp; Long H Ngo; Hasan H Otu; Sharon K Inouye; Sarinnapha M Vasunilashorn; Zara Cooper; Zhongcong Xie; Edward R Marcantonio; Towia A Libermann Journal: Ann Surg Date: 2021-04-01 Impact factor: 12.969
Authors: H M C Shantha Kumara; Elli Sutton; Geoffrey A Bellini; Xiaohong Yan; Vesna Cekic; Nipa Dilip Gandhi; Richard L Whelan Journal: Mol Clin Oncol Date: 2017-12-18
Authors: H M C Shantha Kumara; Erica Pettke; Abhinit Shah; Xiaohong Yan; Vesna Cekic; Melissa Alvarez Downing; Nipa Dilip Gandhi; Richard L Whelan Journal: World J Surg Oncol Date: 2018-07-07 Impact factor: 2.754
Authors: H M C Shantha Kumara; Poppy Addison; Dasuni N Gamage; Erica Pettke; Abhinit Shah; Xiaohong Yan; Vesna Cekic; Richard L Whelan Journal: Mol Clin Oncol Date: 2021-12-08